domestic and international pharmaceutical companies analysis

PPTX 10 sahifa 936,2 KB Bepul yuklash

Sahifa ko'rinishi (5 sahifa)

Pastga aylantiring 👇
1 / 10
powerpoint presentation the foreign and local pharmaceutical companies olimova ezoza 1. domestic market dynamics 2. global pharmaceutical landscape 3. comparative analysis of companies plan: domestic pharmaceutical companies: a national perspective government policies, such as pricing controls and incentives for local drug development (e.g., tax breaks up to 25%), heavily influence the profitability and research & development (r&d) investments of domestic pharmaceutical firms. domestic pharmaceutical companies often face stricter regulatory hurdles, including navigating complex local licensing procedures and undergoing rigorous clinical trials specific to the national market, impacting their overall speed to market compared to multinational corporations. comparative analysis: international vs. domestic strategies regulatory pathways and approval times significantly vary; international firms might navigate longer processes (averaging 12-18 months) for global approvals than domestic firms facing only single-country regulations. international pharmaceutical companies often leverage economies of scale, achieving 20-30% lower production costs compared to their domestic counterparts due to global sourcing …
2 / 10
y rights, including patents, are crucial for pharmaceutical companies, granting them exclusive market rights for a defined period (typically 20 years from the filing date) for their novel drugs, incentivizing r&d. challenges and future outlook the rise of biosimilars and generic competition, impacting ~20% of branded drug markets annually, necessitates innovative strategies like personalized medicine and advanced drug delivery systems for sustained market share and revenue generation. addressing global health inequities, particularly access to essential medicines in low- and middle-income countries (lmics), presents a major ethical and economic challenge, requiring collaborative public-private partnerships and innovative pricing models. innovation and research & development international pharmaceutical companies invest significantly more in r&d than their domestic counterparts, with an average of 15-20% of their revenue allocated to discovering and developing novel drugs and therapies, exceeding domestic company averages. a significant portion (approximately 30-40%) of global pharmaceutical r&d expenditure is concentrated within a handful …
3 / 10
domestic and international pharmaceutical companies analysis - Page 3
4 / 10
domestic and international pharmaceutical companies analysis - Page 4
5 / 10
domestic and international pharmaceutical companies analysis - Page 5

Ko'proq o'qimoqchimisiz?

Barcha 10 sahifani Telegram orqali bepul yuklab oling.

To'liq faylni yuklab olish

"domestic and international pharmaceutical companies analysis" haqida

powerpoint presentation the foreign and local pharmaceutical companies olimova ezoza 1. domestic market dynamics 2. global pharmaceutical landscape 3. comparative analysis of companies plan: domestic pharmaceutical companies: a national perspective government policies, such as pricing controls and incentives for local drug development (e.g., tax breaks up to 25%), heavily influence the profitability and research & development (r&d) investments of domestic pharmaceutical firms. domestic pharmaceutical companies often face stricter regulatory hurdles, including navigating complex local licensing procedures and undergoing rigorous clinical trials specific to the national market, impacting their overall speed to market compared to multinational corporations. comparative analysis: international...

Bu fayl PPTX formatida 10 sahifadan iborat (936,2 KB). "domestic and international pharmaceutical companies analysis"ni yuklab olish uchun chap tomondagi Telegram tugmasini bosing.

Teglar: domestic and international phar… PPTX 10 sahifa Bepul yuklash Telegram